Recombinant covalently closed circular DNA of hepatitis B virus induces long-term viral persistence with chronic hepatitis in a mouse model

Hepatology ◽  
2017 ◽  
Vol 67 (1) ◽  
pp. 56-70 ◽  
Author(s):  
Gaiyun Li ◽  
Yuanfei Zhu ◽  
Dianhui Shao ◽  
Hao Chang ◽  
Xiaoming Zhang ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Mouse Model ◽  
Viral Persistence ◽  
Circular Dna ◽  
Covalently Closed Circular Dna ◽  
B Virus

scholarly journals Detection of Hepatitis B Virus Covalently Closed Circular DNA in the Plasma of Iranian HBeAg-Negative Patients With Chronic Hepatitis B

2015 ◽  
Vol 15 (9) ◽  
Author(s):  
Zahra Tajik ◽  
Hossein Keyvani ◽  
Farah Bokharaei-Salim ◽  
Mohammad Reza Zolfaghari ◽  
Shahin Fakhim ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Circular Dna ◽  
Covalently Closed Circular Dna ◽  
B Virus

scholarly journals Clinical Implications of Hepatitis B Virus RNA and Covalently Closed Circular DNA in Monitoring Patients with Chronic Hepatitis B Today with a Gaze into the Future: The Field Is Unprepared for a Sterilizing Cure

Genes ◽  
2018 ◽  
Vol 9 (10) ◽  
pp. 483 ◽  
Author(s):  
Anastasiya Kostyusheva ◽  
Dmitry Kostyushev ◽  
Sergey Brezgin ◽  
Elena Volchkova ◽  
Vladimir Chulanov
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Splice Variants ◽  
Clinical Implications ◽  
Circular Dna ◽  
Covalently Closed Circular Dna ◽  
Chronic Hepatitis B Virus ◽  
B Virus

. Chronic hepatitis B virus (HBV) infection has long remained a critical global health issue. Covalently closed circular DNA (cccDNA) is a persistent form of the HBV genome that maintains HBV chronicity. Decades of extensive research resulted in the two therapeutic options currently available: nucleot(s)ide analogs and interferon (IFN) therapy. A plethora of reliable markers to monitor HBV patients has been established, including the recently discovered encapsidated pregenomic RNA in serum, which can be used to determine treatment end-points and to predict the susceptibility of patients to IFN. Additionally, HBV RNA splice variants and cccDNA and its epigenetic modifications are associated with the clinical course and risks of hepatocellular carcinoma (HCC) and liver fibrosis. However, new antivirals, including CRISPR/Cas9, APOBEC-mediated degradation of cccDNA, and T-cell therapies aim at completely eliminating HBV, and it is clear that the diagnostic arsenal for defining the long-awaited sterilizing cure is missing. In this review, we discuss the currently available tools for detecting and measuring HBV RNAs and cccDNA, as well as the state-of-the-art in clinical implications of these markers, and debate needs and goals within the context of the sterilizing cure that is soon to come.

Sign in / Sign up

Export Citation Format

Share Document